. However, deletion of GATA6 also causes changes in the morphology, surface markers and gene expression profile of LPMs [9] [10] [11] , illustrating that the study of tissuespecific control of resident macrophage self-renewal can be confounded by substantial effects on macrophage identity. It remains unclear to what extent macrophage self-renewal is regulated in a tissue-specific manner and whether any tissue-specific regulation that does exist cooperates with broadly shared regulators.
In addition to their homeostatic self-renewal capacity, resident macrophages can become alternatively activated in response to type 2 cytokines produced in response to stimuli such as helminth infection, resulting in dramatic proliferation concomitant with acquisition of a pro-repair or anti-helminth protein expression profile [12] [13] [14] [15] . Until recently, proliferation of all macrophages elicited by type 2 immunity was assumed to be controlled by cytokine signaling through JAK kinases and STAT transcription factors. While it remains unclear whether tissue-specific, cell-intrinsic transcriptional regulation influences this process, the collagens SP-A and C1q act through the receptor Myo18a to mediate extrinsic, tissuespecific regulation of proliferation and alternative activation 15 . Signaling through receptors for apoptotic cells also influences these processes in tissue-resident macrophages 16 . Furthermore, differences in alternative activation between monocyte-derived and resident macrophages indicate that ontogeny influences responses during type 2 immunity 17, 18 . Whether there are common regulators of macrophage self-renewal at steady state and proliferation during disease remains unknown.
The transcription factor Bhlhe40 is expressed in some hematopoietic and non-hematopoietic cell types 19, 20 , including select resident macrophage populations 21 . Bhlhe40 binds to DNA at class B E-box motifs and functions primarily as a transcriptional repressor 22, 23 , although examples of transcriptional activation have been described 24, 25 . Bhlhe40 is dysregulated in some cancers and may regulate cell cycling in specific contexts 20 . A variety of hematopoietic cell types are regulated by Bhlhe40, including natural killer T cells and B cells [26] [27] [28] [29] , and it controls cytokine production in T cells during infection and autoimmunity 21, [30] [31] [32] [33] . Bhlhe40 and c-Maf may be interconnected in the regulation of the cytokine IL-10, but how this would occur is unclear 32, 34 . Despite an emerging view that Bhlhe40 is Bhlhe40 mediates tissue-specific control of macrophage proliferation in homeostasis and type 2 immunity Nicholas N. Jarjour 1 an important regulator of immunity, little is known regarding its role in myeloid cells. Bhlhe40 has been proposed as a tissue-specific binding partner of PU.1 in LPMs, but this has not been directly tested 35 .
Here we found that Bhlhe40 had a unique and cell-intrinsic role in LPMs to regulate self-renewal, proliferation and accumulation during type 2 immunity. In LPMs, Bhlhe40 bound a subset of genomic sites bound by the macrophage lineage-specifying transcription factor PU.1, but also many unique sites, including loci encoding cell cycle-related proteins such as c-Maf. Loss of Bhlhe40 in LPMs led to higher expression of Maf and Mafb messenger RNA and lower expression of cell cycle-related transcripts. Our findings establish Bhlhe40 as a tissue-specific transcriptional regulator of LPM proliferation active in both homeostatic self-renewal and on rapid cell cycling during type 2 immunity.
Results
Loss of Bhlhe40 selectively reduces LPMs. Because Bhlhe40 expression has been observed in select resident macrophage populations 21, 36, 37 , we examined macrophages from mice transgenic for a Bhlhe40 GFP bacterial artificial chromosome (Bhlhe40 GFP+ mice hereafter) 21 . We observed low or undetectable GFP expression in Ly6G 
ICAM2
− small pleural macrophages (hereafter, small pleural macrophages) ( Fig. 1a and Supplementary  Fig. 1 ). Of the populations examined, only LPMs and SPMs were decreased in Bhlhe40 -/-compared to Bhlhe40 +/+ mice (Fig. 1b,c and Supplementary Fig. 1 ). In some resident macrophage populations, including LPMs, Tim4 is a marker of embryonically derived, longlived resident macrophages [38] [39] [40] , while CD226 marks mature SPMs 41 .
Decreases in Tim4
+ LPMs and CD226 + SPMs largely accounted for the reduced number of peritoneal macrophages in Bhlhe40 -/-mice ( Supplementary Fig. 1 ). The number of peritoneal CD115 −
MHC-II

+
CD19
+ B cells (hereafter, B cells) was not reduced in Bhlhe40
-/-compared to Bhlhe40 +/+ mice ( Supplementary Fig. 1 ). Therefore, loss of Bhlhe40 selectively reduced the number of LPMs and SPMs.
Bhlhe40 is required in LPMs for self-renewal. To address whether the loss of LPMs in Bhlhe40
-/-mice was due to impaired proliferation, we stained peritoneal cells from Bhlhe40 +/+ and Bhlhe40 -/-mice for Ki67, a marker of cycling cells. We observed a fourfold increase in the frequency of Ki67 + LPMs (Fig. 1d,e ), but little change in the frequency of Ki67 + SPMs and peritoneal B cells in Bhlhe40 -/-compared to Bhlhe40 +/+ mice (Fig. 1e) . Despite normal numbers, we found an increase in the frequency of Ki67 + large pleural macrophages in Bhlhe40 -/-compared to Bhlhe40 +/+ mice ( Supplementary  Fig. 1 ). There was no difference in the uptake of bromodeoxyuridine (BrdU), which is incorporated during the S phase, in LPMs from Bhlhe40 +/+ and Bhlhe40 -/-mice 3 h after injection with BrdU ( Fig. 1f,g ). Staining for the mitosis marker phosphohistone H3 (pHH3) was similar in Bhlhe40 +/+ and Bhlhe40 -/-LPMs (Fig. 1h,i ). When using Ki67 and the nuclear stain 4′,6-diamidino-2-phenylindole (DAPI) to separate the phases of the cell cycle, we observed an increased number of LPMs in the G1 phase (Fig. 1j,k) , but similar numbers of LPMs in the S, G2 and M phases in Bhlhe40 -/-compared to Bhlhe40 +/+ mice (Fig. 1j,k) , suggesting that Bhlhe40 -/-LPMs were impaired in progressing from G1, but proliferated sufficiently to maintain a stable, although reduced, population of LPMs. The proportion of LPMs staining for the viability dye 7-aminoactinomycin D (7-AAD) was similar in Bhlhe40 +/+ and Bhlhe40 -/-mice ( Supplementary Fig. 1 ). Taken together, these data indicated that Bhlhe40 was required for normal proliferation of LPMs.
Bhlhe40 is required intrinsically in LPMs for cell cycling. To address whether the role of Bhlhe40 in LPMs was cell-intrinsic, we generated mixed bone marrow chimeras by co-transfer of equal numbers of Bhlhe40 +/+ (CD45.1) plus either Bhlhe40 +/+ (CD45.2) or Bhlhe40 -/-(CD45.2) total bone marrow cells into irradiated Bhlhe40 +/+ CD45.1/CD45.2 mice, which were allowed to reconstitute for >8 weeks. Of the peritoneal, blood, splenic, liver, kidney, SI lamina propria, lung and pleural hematopoietic populations examined, only LPMs and large pleural macrophages exhibited Bhlhe40-dependent reconstitution (Bhlhe40 +/+ outnumbering Bhlhe40 -/-cells by more than 10:1) (Fig. 2a-d, Supplementary Fig. 2 and data not shown). The small number of Bhlhe40 -/-LPMs in mixed chimeras accumulated in the G1 phase (Fig. 2e,f Supplementary Fig. 2 ), while the relative proportion of transferred Bhlhe40 +/+ (CD45.1) to transferred Bhlhe40 -/-(CD45.2) B cells was maintained in the peritoneum (Fig. 2j,l and Supplementary Fig. 2 ), supporting a cell-intrinsic role for Bhlhe40 in mature LPMs. Thus, Bhlhe40 was cell-intrinsically required in LPMs for normal proliferation and maintenance.
Loss of Bhlhe40 dysregulates a unique set of genes in LPMs.
Next, we performed gene expression microarrays to determine the transcriptional differences between LPMs from Bhlhe40 +/+ and Bhlhe40 -/-mice. A total of 84 genes were dysregulated by twofold or more in Bhlhe40 -/-compared to Bhlhe40 +/+ LPMs (Fig. 3a) , including expression changes in several genes related to macrophage alternative activation, such as Chil3, Clec10a, Mrc1 and Arg1 (Fig. 3b) . We validated these data by flow cytometry for several proteins encoded by differentially expressed genes (Emb, Clec10a, Lyve1) (Fig. 3c-e) . When we assessed the expression of gene ontology sets 42 in the absence of Bhlhe40, using the list of genes that were differentially expressed ≥1.5-fold between Bhlhe40 +/+ and Bhlhe40
-/-LPMs, we found that the regulation of the cell proliferation gene set was enriched in Bhlhe40 +/+ LPMs, while some immune responserelated gene sets were enriched in Bhlhe40 -/-LPMs (Fig. 3f,g ). We validated higher expression of Maf and Mafb mRNA in Bhlhe40 -/-compared to Bhlhe40 +/+ LPMs in our microarrays (data not shown) by reverse transcription-quantitative PCR (RT-qPCR) (Fig. 3h) , consistent with impaired proliferation of Bhlhe40 -/-LPMs. Because the transcription factor GATA6 is an important regulator of LPMs [9] [10] [11] , we reanalyzed our microarray data and published microarray data 11 ). k, Number of LPMs in each phase of the cell cycle as in j. Data in c,e,g,i,k are mean ± s.e.m.; each symbol represents an individual mouse (c,e,g,i,k). *P ≤ 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001, unpaired two-sided Student's t-test. Fig. 3i) . A set of genes selectively expressed in LPMs relative to AMs, splenic red pulp macrophages and microglia has been previously curated 36 . Bhlhe40 regulated the expression of only a small subset of these genes (Lrg1, Stard13, Nedd4) ( Supplementary  Fig. 2 ). Therefore, Bhlhe40 regulated a cell type-specific set of genes in LPMs, but was dispensable for identity.
Bhlhe40 is required for LPM responses during type 2 immunity. We then asked whether Bhlhe40 was required for macrophage accumulation during peritoneal immune responses characterized either by the differentiation of monocyte-derived macrophages or the local proliferation of LPMs. Intraperitoneal (i.p.) injection of thioglycollate, which elicits the recruitment and differentiation of blood-derived monocytes to the peritoneum independent of proliferation 17, 43 , resulted in equivalent accumulation of CD115 + CD11b + ICAM2 lo thioglycollate-elicited macrophages (hereafter, thioglycollate-elicited macrophages) in Bhlhe40 +/+ and Bhlhe40 -/-mice after four days (Fig. 4a,b) , while the i.p injection of IL-4 + anti-IL-4 antibody complexes (hereafter, IL-4c), which elicit the robust proliferation of resident macrophages 12 , caused a fivefold increase in the number of LPMs in Bhlhe40 +/+ mice compared to Bhlhe40 -/-mice after four days (Fig. 4c,d 
Bhlhe40
-/-Il10 -/-mice had poor accumulation of LPMs after injection of IL-4c ( Supplementary Fig. 3 (Fig. 5a,b) (Fig. 5c,d ). IL-4c treatment also elicited a greater increase in the fraction of LPMs in the G1, S and G2M phases of the cell cycle in Bhlhe40 +/+ compared to Bhlhe40 -/-mice (Fig. 5e ). Immunoblot analysis of cyclins D1-D3, cyclin-dependent kinase (CDK) 2, CDK4, CDK6 and the transcription factor E2F2, which regulate the G1 and S phases of the cell cycle 44 , showed increases in cyclin D3, CDK2 and CDK4 in LPMs from IL-4c-treated compared to naïve mice ( Supplementary Fig. 3) ; however, their abundance was generally similar in Bhlhe40 +/+ and Bhlhe40 -/-LPMs ( Supplementary Fig. 3 ). In contrast to cyclins and CDKs, E2F2 was similar in LPMs from mice injected or not with IL-4c ( Supplementary Fig. 3 (Fig. 5f ). In mixed bone marrow chimeras (generated and reconstituted as in 
LPMs incorporated BrdU compared to Bhlhe40
+/+ LPMs within the same recipient ( Supplementary Fig. 3 ).
We used transmission electron microscopy of bulk peritoneal cells from naïve and IL-4c-treated Bhlhe40 +/+ and Bhlhe40 -/-mice to assess cell morphology. Bhlhe40 +/+ and Bhlhe40 -/-LPMs from IL-4c-treated mice showed increases in cell size and endoplasmic reticulum (ER) extent compared to naïve LPMs ( Supplementary Fig. 4 ). We observed no distinct morphology between naïve Bhlhe40 -/-and Bhlhe40 +/+ LPMs, while LPMs from IL-4c-treated Bhlhe40 -/-mice were somewhat larger and more vacuolated than LPMs from IL-4c-treated Bhlhe40 +/+ mice, without any severe morphologic defects 
, red pulp macrophages, AMs (both pooled from six experiments, n = 13 [Bhlhe40 ( Supplementary Fig. 4 ). Therefore, Bhlhe40 was required for LPMs to rapidly cycle in response to IL-4c, but was dispensable for normal morphology and induction of alternative activation markers.
Monocytes can acquire a Bhlhe40-dependent proliferative program. Next, we asked whether Bhlhe40 was required for the IL-4c-induced proliferation of other macrophages. IL-4c injection i.p.
into Bhlhe40 GFP+ mice did not change the expression of GFP in LPMs, SPMs, AMs, kidney macrophages, red pulp macrophages and Kupffer cells compared to these populations in PBS-treated Bhlhe40 GFP+ mice ( Supplementary Fig. 5 ). IL-4c injection i.p. into Bhlhe40 +/+ and Bhlhe40 -/-mice resulted in equivalent BrdU incorporation by, and numbers of, red pulp macrophages, Kupffer cells and AMs ( 
Bhlhe40
+/+ (CD45.1) 
). i, Gene expression microarray data were analyzed for shared and unique Bhlhe40-dependent genes in Bhlhe40 +/+ and Bhlhe40 -/-LPMs and AMs (≥2-fold differentially expressed, depicted as a Venn diagram). Heat map depicts all genes differentially expressed by ≥ 2-fold in Bhlhe40 +/+ and Bhlhe40 -/-AMs. Microarray data from LPMs (n = 3 per group) and AMs (n = 2 per group) are from a single experiment. Data in c-e,h are mean ± s.e.m.; each symbol represents an individual mouse (c-e,h). *P ≤ 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001, unpaired two-sided Student's t-test (c-e,h) and one-sided hypergeometric test (f,g). and large pleural macrophages, which required Bhlhe40 for a normal population of BrdU-incorporating cells in response to IL-4c ( Fig. 5g and Supplementary Fig. 5 ).
Injection of thioglycollate and IL-4c i.p. causes monocytederived macrophages to proliferate and acquire alternative activation markers 17, 18 . When we asked whether Bhlhe40 was expressed in these monocyte-derived macrophages, we found that the combination of thioglycollate and IL-4c induced marked expression of GFP in the thioglycollate-elicited macrophages in Bhlhe40 GFP+ mice compared to a lower expression of GFP in macrophages elicited by thioglycollate alone (Fig. 5h) . After treatment with thioglycollate and IL-4c, Bhlhe40 -/-mice had severely reduced proportions of BrdU + and pHH3 + thioglycollate-elicited macrophages compared to Bhlhe40 +/+ mice (Fig. 5i,j and Supplementary Fig. 6 ), while RELMα was acquired normally (Supplementary Fig. 6 ). Thus, these data indicated that Bhlhe40 is a specific regulator of large serous cavity macrophage proliferation in response to IL-4c and that monocytederived macrophages can acquire a Bhlhe40-dependent proliferative program similar to that of serous cavity resident macrophages. -/-mice after eight days (Fig. 6a,b (Fig. 6c,d ). H. polygyrus infection elicited a greater increase in the fraction of LPMs in the G1, S and G2M phases of the cell cycle in Bhlhe40 +/+ compared to Bhlhe40 -/-mice (Fig. 6e) . The proportion of 7-AAD + necrotic LPMs was also increased in Bhlhe40 -/-and LysM-Cre + Bhlhe40
Bhlhe40 regulates LPM proliferation in response to
fl/fl compared to Bhlhe40 +/+ and LysM-Cre -Bhlhe40 fl/fl infected mice (Fig. 6f) . These data suggested that Bhlhe40 is essential for the proliferation of LPMs during type 2 immunity. +/+ and Bhlhe40 -/-mice compared to LPMs from naïve Bhlhe40 +/+ and Bhlhe40 -/-mice (87 genes; Fig. 7a-c) . To ask whether the transcriptional changes that occurred in alternatively activated LPMs were dependent on Bhlhe40, we selected the 55 genes most differentially expressed (≥10-fold different) between naïve and IL-4c-treated Bhlhe40 +/+ LPMs, including Mgl2, Chil3, Arg1 and Il1rl1 (Fig. 7d) . These genes were generally normally expressed in Bhlhe40
Bhlhe40
-/-and LysM-Cre + Bhlhe40 fl/fl LPMs from IL-4c-treated mice (Fig. 7d) , and we also found no defect in the expression of Myo18a, C1qa, C1qb and C1qc, which encode known regulators of LPM proliferation during type 2 immune responses 15 ( Supplementary Fig. 7) . Consistent with impaired proliferation, Maf (3.2-fold) and Mafb (3.8-fold) were more highly expressed in Bhlhe40 -/-compared to Bhlhe40 +/+ LPMs by RT-qPCR (Fig. 7e) . Gene-set enrichment analysis (GSEA) for Hallmark gene sets 45 showed prominent enrichment of gene sets related to proliferation, including the E2F targets and Myc targets v1 gene sets, in the gene expression data between LPMs from IL-4c-treated Bhlhe40
and Bhlhe40 -/-mice (Fig. 7f) . Further comparison of differentially expressed genes to the C5 gene ontology sets indicated that LPMs from IL-4c-treated Bhlhe40 +/+ mice were substantially enriched for cell cycle and chromosome-related gene sets (cell cycle, cell cycle process, mitotic cell cycle), while LPMs from IL-4c-treated Bhlhe40 -/-mice showed enrichment for the vacuole gene set (Fig. 7g-i) , consistent with increased vacuolar area by electron microscopy. Therefore, Bhlhe40 was required in LPMs for normal regulation of cell cycle-related gene expression.
Bhlhe40 targets cell cycle-related loci directly. We next addressed whether Bhlhe40 regulated LPM gene expression via direct binding to gene loci by sorting LPMs from naïve and IL-4c-treated Bhlhe40
+/+ mice after four days for Bhlhe40 chromatin immunoprecipitation sequencing (ChIP-seq). Motif analysis of the called peaks identified the expected CACGTG E-box sequence (Fig. 8a) and a majority of Bhlhe40 peaks (naïve 2,245 total peaks; IL-4c-treated 5,011 total peaks) were promoter-associated in both samples (Fig. 8b) . In both conditions, Bhlhe40 bound sites in the Bhlhe40 (single peak, within promoter) and Il10 (single peak, 1 kilobase (kb) downstream of locus) loci previously described in T cells (Fig. 8c and Supplementary Fig. 7 ) 33 . We also identified a novel Bhlhe40 binding site 1.5 kb downstream of the Bhlhe40 locus that was occupied only in LPMs from IL-4c-treated mice (Fig. 8c) . Many Bhlhe40 peaks were shared between LPMs from naïve and IL-4c-treated mice (1,684 sites, including peaks proximal to the Klf4, Nr1d1, Plac8 and Yy1 loci) (Fig. 8d) , but the majority were unique to LPMs from IL-4c-treated mice (3,364 sites, including peaks proximal to the Klf4 and Nr1d1 loci) (Fig. 8d) , often in association with shared peaks (as for the Bhlhe40 locus).
Because Bhlhe40 and PU.1 may cooperate in LPMs 35 , we compared our ChIP-seq data with previously published PU.1 ChIP-seq performed on LPMs from naïve C57BL/6 mice 35 . PU.1 peaks overlapped with 22% or 24% of Bhlhe40 peaks in LPMs from naïve or IL-4c-treated mice, respectively, including the Clec10a, Ccl2 and Plac8 loci (Fig. 8e,f and Supplementary Fig. 7) . However, the majority of Bhlhe40 peaks (naïve 1,754 peaks; IL-4c 3,822 peaks) were not associated with PU.1 binding (Fig. 8f) , including at the Bhlhe40, Maf and Il10 loci. When we assessed whether Bhlhe40 bound directly to genes with Bhlhe40-dependent expression, we found that Bhlhe40 bound a small fraction of genes differentially expressed by twofold or more between LPMs from naïve Bhlhe40 +/+ and Bhlhe40 -/-mice (11% of genes downregulated in Bhlhe40 -/-LPMs, 17% of genes upregulated in Bhlhe40 -/-LPMs; Fig. 8g and Supplementary  Fig. 7 ) and bound a greater fraction of genes differentially expressed between LPMs from IL-4c-treated Bhlhe40 +/+ and Bhlhe40 -/-mice (15% of genes downregulated in Bhlhe40 -/-LPMs, 48% of genes upregulated in Bhlhe40 -/-LPMs; Fig. 8g and Supplementary Fig. 7 ), suggesting a direct role for Bhlhe40 in regulating gene expression in LPMs.
Further analysis of our ChIP-seq data identified a Bhlhe40 peak within the Maf promoter in LPMs from naïve or IL-4c-treated mice (Fig. 8h) , as well as two additional peaks closest to the Maf locus (200 kb downstream (naïve and IL-4c) and 300 kb downstream (IL-4c) of the locus) ( Supplementary Fig. 7 ), suggesting that Bhlhe40 repressed the Maf locus. There was no clear Bhlhe40 peak uniquely associated with the Mafb locus ( Supplementary Fig. 7 ). To address whether Bhlhe40 directly regulated other cell cycle-related loci, we performed GSEA analysis for the subset of genes directly bound by Bhlhe40 using the gene expression data from LPMs from IL-4c-treated Bhlhe40 +/+ and Bhlhe40 -/-mice. We found that differential expression of these genes between Bhlhe40 +/+ and Bhlhe40 -/-LPMs from IL-4c-treated mice largely recapitulated the enrichment of cell cycle-related modules observed when all gene expression data were analyzed ( Fig. 8i and Supplementary Fig. 8 ). Thus, Bhlhe40 functioned in LPMs as a direct transcriptional regulator of numerous genomic loci, including those encoding cell cycle-related proteins.
Discussion
Here we found that the transcription factor Bhlhe40 was an essential cell-intrinsic regulator of proliferation in LPMs. In the steady state, Bhlhe40 -/-LPMs were reduced in number and a higher proportion accumulated in the G1 phase compared to Bhlhe40 +/+ LPMs. During type 2 immunity, Bhlhe40 was essential for normal proliferation and accumulation, with a reduced proportion of Bhlhe40 -/-LPMs in the S and M phases compared to Bhlhe40
LPMs, but Bhlhe40 was dispensable for acquisition of alternative a-d,f,g,j) . *P ≤ 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001, unpaired two-sided Student's t-test. activation markers. Bhlhe40 mediated repression of Maf and activation of multiple proliferation-related loci to allow LPM cell cycling. Bhlhe40 was a tissue-specific regulator of proliferation of LPMs, but could be acquired by peritoneal monocyte-derived macrophages to support a proliferative program.
How deletion of Bhlhe40 impairs cell cycle progression of LPMs remains unclear. We observed that a higher proportion of Bhlhe40 -/-LPMs were Ki67 + compared to Bhlhe40 +/+ LPMs, suggesting that Bhlhe40 -/-LPMs might inappropriately enter the cell cycle. However, our data are not consistent with this notion, as we saw a selective increase in the proportion of Bhlhe40 -/-LPMs in the G1 phase, without a commensurate increase in LPMs in the S, G2 or M phases. Both Bhlhe40 +/+ and Bhlhe40 -/-LPMs upregulated cyclins and CDKs when mice were treated with IL-4c. In contrast, Bhlhe40 +/+ and Bhlhe40 -/-LPMs had low expression of cyclins and CDKs at steady state. These data support the notion that impaired progression from the G1 phase rather than enhanced proliferation was the primary cause of accumulation of G1 phase LPMs in naïve and probably IL-4c-treated Bhlhe40 -/-mice. As expression of cyclin D and CDKs were comparable between Bhlhe40 +/+ and Bhlhe40 LPMs, alterations solely in the expression of these regulators probably do not explain the effect of Bhlhe40 deficiency on LPM proliferation. Instead, the phenotype of Bhlhe40 -/-LPMs was probably due to the impaired transcriptional regulation of a broad set of cell cycle-related genes caused by loss of Bhlhe40 and upregulation of c-Maf and MafB.
Bhlhe40 and c-Maf may functionally interact in T cells 32, 34 . Our data suggest that Bhlhe40 is a transcriptional repressor of Maf in LPMs. In contrast to T cells and other tissue-resident macrophages, LPMs require Bhlhe40 to support normal proliferation, suggesting that Bhlhe40-mediated repression of Maf has distinct effects in different cell types. Expression of both Bhlhe40 and c-Maf in LPMs results in a unique regulatory interaction not detected in macrophage subsets lacking expression of one of these transcription factors. Downregulation of Maf and Mafb expression is critical for proliferation in macrophages 6, 7 . Our data are most consistent with a role for Bhlhe40 in repressing Maf and Mafb to permit LPM cell cycling, along with Bhlhe40-mediated regulation of a wider set of target genes, some of them co-bound by PU.1, as previously proposed 35 . It is likely that specific networks of integrated transcriptional regulators control the development and function of resident macrophages in each tissue. In LPMs, this network would include Bhlhe40, PU.1 (ref. 35 ), c-Maf 7 and MafB
7
, as well as GATA6 (refs. [9] [10] [11] ) and C/EBPβ (ref. 46 ), two transcription factors whose loss results in impaired development of LPMs.
In addition to LPMs and large pleural macrophages, AMs and, in some contexts, monocyte-derived macrophages expressed Bhlhe40.
Bhlhe40
-/-AMs only showed minor transcriptional differences compared to Bhlhe40 +/+ AMs and no evidence of a proliferative defect. c-Maf and MafB were poorly expressed in AMs 7 and were not induced in Bhlhe40 -/-AMs (data not shown), suggesting that Bhlhe40 was not required to repress these transcription factors in AMs. It is also possible that Bhlhe41, which is expressed highly in AMs but not LPMs (data not shown) and can partially substitute for Bhlhe40 (ref. 28 ), may compensate for the absence of Bhlhe40 in AMs. In contrast to AMs, monocyte-derived macrophages can acquire a Bhlhe40-dependent proliferative program in response to thioglycollate and IL-4c. The similarities of this Bhlhe40-regulated transcriptional program in monocyte-derived macrophages to that of LPMs remain to be explored. ). Data in b-f are mean ± s.e.m.; each symbol represents an individual mouse (b-d,f). *P ≤ 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001, unpaired two-sided Student's t-test. 0 2 ,000 4,000 6,000 8,000
Regulation of intracellular signal transduction 
IL-4c Naive IL-4c Naive 0 5 0 1 00 150 ). f,g, GSEA of gene expression microarray data for representative Hallmark (f) and C5 gene sets (g) enriched in Bhlhe40 +/+ versus Bhlhe40 -/-LPMs from IL-4c-treated mice. NES, normalized enrichment score. FWER, family-wise error rate. h,i, MSigDB C5 gene-set enrichment was analyzed using the lists of genes expressed at ≥1.5-fold in Bhlhe40 +/+ versus Bhlhe40 -/-(h) or Bhlhe40 -/-versus Bhlhe40 +/+ (i) LPMs from IL-4c-treated mice. Microarray data from naïve LPMs (n = 3 per group, reanalyzed from Fig. 3 ) and in vivo IL-4c-stimulated LPMs (n = 2 per group) are from single separate experiments. Data in e are mean ± s.e.m.; each symbol represents an individual mouse (e). ***P < 0.001; ****P < 0.0001, unpaired two-sided Student's t-test (e), NES and FWER (f,g) and one-sided hypergeometric test (h,i).
Whether common regulators can control macrophage cell cycling in response to different stimuli during homeostasis (for example CSF-1) or type 2 immunity (for example IL-4 or IL-13) 13 is unclear. Our findings demonstrate the existence of shared regulation of macrophage proliferation in the steady state and disease, as well as a crucial role for tissue-specific transcriptional regulation acting in concert with more broadly shared regulators such as c-Maf. This suggests the possibility of therapeutically targeting the proliferation of select macrophage populations, including tumorassociated macrophages, which are known to partly derive from tissue-resident macrophages and to locally proliferate [47] [48] [49] [50] . Our results illustrate the complexity of tissue-specific control of macrophages, demonstrating that tissue-specific transcription factors are critical for the regulation of macrophage proliferation in health and disease. Our data provide direct evidence that resident macrophages are under constant control by a partnership of shared and tissue-specific transcription factors, with possible implications for therapies.
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Methods
Mice. C57BL/6 (Taconic), B6.SJL (CD45.1, Taconic or Jackson), Il10 -/-(B6.129P2-Il10tm1Cgn/J, Jackson) and LysM-Cre (B6N.129P2(B6)-Lyz2 tm1(cre)Ifo /J, Jackson) mice were obtained from the vendors listed. Bhlhe40 -/-(ten generations backcrossed to the C57BL/6 background) 31, 51 , Bhlhe40 GFP+ (ten generations backcrossed to the C57BL/6 background) 21 and Bhlhe40 fl/fl (ref. 33 ) mice have been previously reported. The Bhlhe40 GFP+ mouse strain, originally defined as STOCK Tg(Bhlhe40-EGFP)PX84Gsat/Mmucd, identification number 034730-UCD, was obtained from the Mutant Mouse Regional Resource Center (MMRRC), a National Center for Research Resources (NCRR)-NIH funded strain repository, and was donated to the MMRRC by the National Institute of Neurological Disorders and Stroke (NINDS)-funded GENSAT BAC transgenic project (The GENSAT Project, NINDS Contract N01NS02331 to the Rockefeller University). All mice were maintained in our specific pathogen-free animal facility. Sex-matched littermates were used for experiments whenever possible, although in some cases mice from multiple litters were used in a single experiment. All animal experiments were approved by the Animal Studies Committee of Washington University in St. Louis.
Bone marrow chimeras. Bhlhe40
+/+ CD45.1/CD45.2 mice were lethally irradiated with 1,000 rads from a gamma irradiator, followed by same-day intravenous transfer of 16 million total bone marrow cells (8 
Treatment of mice with thioglycollate and IL-4c complexes.
A 3% solution of thioglycollate was prepared in water, autoclaved and aged for three or more months 43 . Mice received 1 ml i.p. to induce peritonitis or a control injection of PBS 43 . IL-4c complexes were prepared fresh as described 12, 52 . IL-4 (Shenandoah Biotechnology, catalog no. 200-18, resuspended in 0.1% BSA in water) and anti-IL-4 (clone 11B11; Leinco I-1071 or BioXCell BE0045) were combined in a 1:5 ratio by mass and a 1:1 ratio by volume, using ~1 mg ml −1 cytokine and ~5 mg ml −1 antibody. Complexes were incubated for ~2 min at room temperature, diluted in 1× Dulbecco's PBS (DPBS) and injected i.p. Control injections were 0.1% BSA diluted in 1× DPBS, while naïve mice were also used for assessment of cell cycling, due to acquisition of Ki67 + by LPMs 2 days after PBS injection, as described 13 . Mice received injections on day 0 and day 2, followed by sacrifice on day 4, as described 12 . For treatment with thioglycollate and IL-4c complexes, mice were injected i.p. with thioglycollate on day 0 and IL-4c on days 0 and 2, as previously described 17, 18 . H. polygyrus infections. H. polygyrus bakeri third-stage larvae (L3) were prepared as described 53 . Mice were orally gavaged with 200 L3 or water (mock) with a 20-gauge ball-tipped gavage needle. Mice were killed on day 8 of infection for assessment of peritoneal cells.
Leukocyte collection from tissue. Peritoneal and pleural cells were collected from body cavities by lavage. Bone marrow was collected by flushing hind limb femurs and tibias. Blood was collected by submandibular bleeding into EDTA or lithium heparin tubes. Lungs, liver, spleen and kidney were excised, placed in IMDM containing 5% fetal bovine serum (FBS), minced finely and digested at 37 °C for an hour with mechanical disruption with a stir bar and enzymatic digestion (lung and kidneys, 4 mg ml −1 collagenase D (Roche); spleen, 0.25 g ml −1 collagenase B (Roche) and 30 U ml −1 DNase I (EMD); liver, 4 mg ml −1 collagenase D and 30 U ml −1 DNase I). Microglia 21 and small intestinal lamina propria cells 54 were isolated as described. After digestion, enzymes were inactivated with 5 mM EDTA and samples were incubated on ice for 5 min.
All cells were passed through a 70-μm cell strainer before analysis. If necessary, tissues were treated with ACK lysis buffer to lyse red blood cells. Cells were counted with a hemocytometer using 3% acetic acid (naïve peritoneum and pleura) or trypan blue (all others).
Flow cytometry. Cell surface staining was conducted in sterile 1× PBS with 0.5% BSA and 2 mM EDTA (hereafter, FACS buffer). In brief, cells were washed in FACS buffer, blocked with α-CD16/32 (clone 2.4G2, BioXCell) for 10 min at 4 °C, stained for 20 min at 4 °C and washed with FACS buffer before flow cytometry. In some experiments to assess cell death, 7-AAD (1:20 of a 50 μg ml −1 solution, BioLegend or BD) was added to cells for 15 min prior to flow cytometry. Flow cytometry was performed on FACSCanto II, LSRFortessa, LSRFortessa X20 and LSR II instruments (all BD). FlowJo software (Treestar) was used for analysis. Antibodies and fluorescent dyes used in this study are listed in Supplementary Table 1 .
Gating of cell populations was as follows (all analysis pre-gated on FSC/SSC and a FSC−W/FSC-A singlet gate). Blood monocytes were gated as Ly6G GFP+ reporter mouse used viability dyes (Po pro 1 or 7-AAD) when necessary to exclude dead cells.
Intracellular staining for flow cytometry. For Ki67, DAPI, RELMα, BrdU and pHH3 staining, the eBioscience FoxP3/Transcription Factor Staining Buffer set (00−5523-00) or the BioLegend True-Nuclear Transcription Factor Buffer set (424401) was used. In brief, after surface staining, cells were fixed with 1× Fix Concentrate buffer in the provided Fix Diluent for 30 min at 4 °C. Cells were then washed with FACS buffer and stored overnight. To permeabilize the cells, samples were washed with 1× Perm buffer diluted in water. Following blocking with 2% rat serum, samples were stained for 1 h at room temperature, except for DAPI and secondary antibodies (20 min at room temperature), followed by washing in 1× Perm buffer and FACS buffer before flow cytometry.
For BrdU staining, mice were given 1 mg of BrdU i.p. (from BD kit, 552598, or Sigma, B5002) 3 h before killing as described 12 . After killing of mice and peritoneal lavage, samples were processed, fixed and stored overnight as for other intracellular antigens. BrdU-labeled cells were washed in 1× Perm buffer, incubated in DNase I (from BD kit, 552598, or Sigma, D4513) in 1× DPBS for 30 min at 37 °C, washed in 1 x Perm buffer, blocked with 2% rat serum and stained for 1 h at room temperature with α-BrdU antibody (BD, 552598), followed by washing in 1× Perm buffer and FACS buffer. Mice that did not receive BrdU were used as negative controls.
Transmission electron microscopy. For ultrastructural analyses, peritoneal cells were fixed in 2% PFA/2.5% glutaraldehyde (Polysciences Inc.) in 100 mM sodium cacodylate buffer, pH 7.2 for 1 h at room temperature. Samples were washed in sodium cacodylate buffer at room temperature and postfixed in 1% osmium tetroxide (Polysciences Inc.) for 1 h. Samples were rinsed in distilled water prior to en bloc staining with 1% aqueous uranyl acetate (Ted Pella Inc.) for 1 h. Following rinsing in distilled water, samples were dehydrated in a graded series of ethanol and embedded in Eponate 12 resin (Ted Pella Inc.). Sections of 95 nm were cut with a Leica Ultracut UCT ultramicrotome, stained with uranyl acetate and lead citrate and viewed on a JEOL 1200 EX transmission electron microscope (JEOL USA Inc.) equipped with an AMT 8 megapixel digital camera and AMT Image Capture Engine v.602 software (Advanced Microscopy Techniques).
For morphological analysis, images were blinded and randomized. LPMs were identified as large cells with abundant cytoplasm and were distinguished from rare peritoneal mast cells by the absence of electron-dense granules. For measurement statistics, the ObjectJ plugin was used in ImageJ software (NIH). In brief, cell and vesicle cross-sectional area were calculated by tracing the outline of the cell or vesicles, respectively, and calculating the enclosed area. ER cross-sectional extent was calculated by tracing the ER with lines and adding these lengths together. For assessment of ER luminal width, a randomly placed grid was used to subdivide the cell into sections. Representative measurements were then taken across the lumen of the ER, and the measurements from each section were averaged. 
Ly6G
− Siglec-F + CD11c + CD11b lo AMs from untreated mice. Cells were lysed and RNA was purified using the E.Z.N.A. MicroElute Total RNA kit (Omega Bio-Tek). Total RNA was submitted to the Genome Technology Access core at Washington University for cDNA synthesis (NuGen Pico SL) followed by microarray analysis on the Affymetrix Mouse Gene 1.0 ST platform. Data were analyzed using the ArrayStar program (DNASTAR). Genes with an expression value of <5 (in log 2 scale) in all replicates were considered not expressed. For analysis of naïve microarrays, which were conducted on three biologic replicates, the differentially expressed gene list was also filtered on genes with a P value significance of ≤0.05 by the moderated t-test. For analysis of in vivo IL-4c-stimulated LPM microarrays, which were conducted on two biologic replicates, no P value filtering was applied. For comparison of naïve to in vivo IL-4c-stimulated LPMs, CEL files were normalized together to generate expression data. Heat maps were generated with Morpheus (https://software.broadinstitute.org/morpheus/). Venn diagrams were generated with the Venn Diagram Plotter tool (Pacific Northwest National Laboratories, omics.pnl.gov). Multiple differentially expressed probe sets representing a single gene were presented in heat maps without exclusion, but only unique genes were counted in Venn diagrams.
